Xcovery

Xcovery's Xalkori challenger shines in phase 3

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

Amirah Al Idrus Aug 8, 2020 7:00am

Soon-Shiong sued over Abraxane rival drug buy—Chutes & Ladders

Apr 5, 2019 9:30am

Xcovery hires CEO, CMO to lead assault on ALK NSCLC market

Mar 29, 2019 11:02am